IDEXX Laboratories, Inc. (IDXX) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. IDEXX Laboratories, Inc. operates primarily through three reportable segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD). The company develops, manufactures, and distributes diagnostic products and services for the veterinary, livestock, and water testing sectors.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $1,216.6 million | $1,109.5 million | $2,357.4 million | $2,107.9 million |
| Net Income | $338.4 million | $294.0 million | $616.9 million | $536.7 million |
| Diluted EPS | $4.27 | $3.63 | $7.74 | $6.59 |
| Gross Margin | 64.0% | 62.6% | 63.7% | 62.5% |
| Operating Income | $425.6 million | $373.0 million | $788.2 million | $689.6 million |
| Operating Cash Flow (YTD) | $613.4 million (vs. $423.7 million YTD 2025) | |||
| Cash & Equivalents | $196.9 million (as of June 30, 2026) | |||
| Total Debt | $969.0 million (Gross Debt) | |||
| Net Debt to Adjusted EBITDA | 0.46x |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 9.7% in Q2 and 11.8% YTD compared to the prior year. Organic revenue growth was 9.0% in Q2 and 10.0% YTD.
- Segment Performance:
- CAG: Revenue grew 9.4% in Q2, driven by higher volumes in VetLab consumables and reference lab services. Instrument revenue declined 19.5% due to lower placements of the inVue Dx Analyzer compared to the prior year.
- Water: Revenue grew 14.8% in Q2, supported by higher demand for Colilert products and favorable pricing.
- LPD: Revenue grew 10.8% in Q2, driven by increased test volumes in the Americas and Europe.
- Profitability: Gross margin expanded 140 basis points in Q2 to 64.0%, benefiting from operational productivity, favorable product mix, and price realization offsetting inflation.
- Expenses: Operating expenses increased 9.9% in Q2. General and administrative expenses rose 18.4% year-over-year, partially due to a $5 million impairment charge on an equity investment in Q1 2026 and higher personnel costs.
Guidance, Outlook, and Risks
- Capital Allocation: The company repurchased approximately $332.3 million of common stock in Q2 2026. As of June 30, 2026, approximately 2.55 million shares remained available under the repurchase program.
- Debt Maturities: The company anticipates funding the full repayment of $75.0 million in 2026 Senior Notes due September 4, 2026, and $75.0 million in 2027 Series B Notes due February 12, 2027, using cash on hand or borrowings.
- Capital Expenditures: Total capital expenditure plan for 2026 is estimated at approximately $180.0 million.
- Foreign Currency: Management anticipates that year-over-year currency changes for the remainder of 2026 will decrease revenues by approximately $13 million but increase operating profit by $2 million and diluted EPS by $0.02.
- Risks: Key risks include global conflicts impacting supply chains, inflationary pressures on labor and commodities, and the potential for future effective tax rates to increase due to the elimination of certain share-based compensation tax benefits.
Investor Verification Checklist
- Instrument Revenue Trend: Verify the sustainability of the decline in CAG instrument revenue and the impact of the inVue Dx Analyzer placement cycle.
- Equity Investment Impairment: Confirm the nature of the $5 million impairment charge recorded in Q1 2026 and assess if further impairments are likely.
- Debt Refinancing: Monitor the execution of the $75 million Senior Note repayment in September 2026 and the associated refinancing strategy.
- Share Repurchase Pace: Track the remaining $2.55 million share repurchase authorization and the company's commitment to returning capital amidst debt obligations.
- Organic Growth Drivers: Assess the durability of the 10%+ organic growth rate, specifically the contribution from price realization versus volume growth in the CAG segment.